Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;43(1):147-56.
doi: 10.1007/s11255-010-9744-5. Epub 2010 May 7.

Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data

Tom Cornelis  1 , Dimitrios G Oreopoulos
Affiliations
Review

Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data

Tom Cornelis et al. Int Urol Nephrol. 2011 Mar.

Abstract

Encapsulating peritoneal sclerosis (EPS) is an infrequent but serious complication of peritoneal dialysis (PD). The pathogenesis is unknown but speculation is ongoing. The current management of EPS focuses on prevention and treatment of the inflammatory and fibrotic changes at the level of the peritoneal membrane with immunosuppressive and antifibrotic agents, respectively. This article reviews the currently available human and animal data on potential agents to prevent and/or treat EPS. We propose a strategy for early diagnose EPS in an attempt to avoid the development of the full-blown and potentially life-threatening clinical syndrome of EPS. Future research should focus on studying potential prophylactic and therapeutic agents in humans in large, multicenter, randomized trials but also on early detection of EPS in the inflammatory phase by means of biomarkers and the establishment of a composite EPS score.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proposed options for prevention (arrows 1-3) and treatment (arrow 4) of encapsulating peritoneal sclerosis
See this image and copyright information in PMC

References

    1. Nakamoto H. Encapsulating Peritoneal Sclerosis—a clinician′s approach to diagnosis and medical treatment. Perit Dial Int. 2005;25(Suppl 4):30–38. - PubMed
    1. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, Maes R, Struijk DG, Krediet RT. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int. 2009;29(5):517–522. - PubMed
    1. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nakamoto M, Ohira S, Shoji T. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44(4):729–737. - PubMed
    1. Korte MR, Yo M, Betjes M, Fieren MW, van Saase JC, Boer WH, Weimar W, Zietse R. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant. 2007;22(8):2412–2414. doi: 10.1093/ndt/gfm171. - DOI - PubMed
    1. Yañez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan J, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003;348(5):403–413. doi: 10.1056/NEJMoa020809. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources